SCN1A rs2298771: Antiepileptic Drug Response and Biology
The rs2298771 single nucleotide polymorphism is a common missense variant in the SCN1A gene, resulting in a threonine-to-alanine amino acid substitution (p.Thr1067Ala). Researchers have widely studied this variant for its potential relationship with epilepsy susceptibility and clinical responsiveness to sodium-channel-blocking antiepileptic drugs such as carbamazepine and valproate. However, clinical evidence remains mixed and inconclusive, meaning the variant is not currently used to guide medication prescribing in routine medical practice.
What each genotype means
Potential drug response variation
Research into this genotype suggests it may influence how your body responds to certain antiepileptic medications, such as carbamazepine or valproate. Some studies indicate that carriers of the C allele may have different remission or response rates compared to those with the T allele, though findings are mixed and often specific to certain populations or drug regimens. Please discuss your medication management and any concerns about treatment efficacy with your neurologist or pharmacist.
Carried by approximately 30% of individuals of European ancestry, but frequency varies significantly by global population, being less common in East Asian groups.
Potential drug response variation
This genotype represents a heterozygous state for the SCN1A variant, which has been studied for its potential role in antiepileptic drug responsiveness. While some clinical reports suggest an association between this variant and drug resistance or efficacy, the evidence remains limited and inconsistent across different studies. You should consult with your healthcare provider to determine if this information is relevant to your specific treatment plan.
This is a common genotype found across most global populations, reflecting the high prevalence of both the C and T alleles in the general public.
Potential drug response variation
As a carrier of the TT genotype, you possess the variant often used as a reference point in studies examining sodium-channel-blocking antiepileptic drugs. Some research has observed that individuals with this genotype may show different response patterns to medications like valproate compared to those with the C allele, though these results are not universal. Always coordinate with your clinical team regarding your epilepsy treatment, as many factors beyond this single genetic marker influence drug response.
This is the most frequent genotype in many populations, particularly in East Asian groups where the T allele is highly prevalent.
Genetic Location and Molecular Characterization
The rs2298771 variant is an exonic single nucleotide polymorphism located within the SCN1A gene on human chromosome 2. At the complementary DNA level, it represents an adenine-to-guanine change designated as c.3184A>G. Because genomic databases occasionally report genotypes using the plus chromosomal strand (where the substitution corresponds to thymine to cytosine), literature notations may reference either A/G or T/C alleles. At the protein level, this alteration results in a substitution of threonine with alanine at position 1067 (p.Thr1067Ala), occurring within an intracellular linker domain of the sodium channel alpha subunit. Unlike severe loss-of-function de novo mutations in SCN1A that cause rare, severe developmental epileptic encephalopathies like Dravet syndrome, rs2298771 is a common, naturally occurring polymorphism found widely in general human populations across the world.
Biological Function of the SCN1A Gene
The SCN1A gene provides the genetic blueprint for the alpha subunit of Nav1.1, a voltage-gated sodium channel predominantly expressed in the central nervous system. Nav1.1 plays an essential role in the initiation and propagation of action potentials, particularly in inhibitory GABAergic interneurons. In these interneurons, functional sodium channels are critical for dampening excessive neuronal excitability across neural networks. Because Nav1.1 channels are targeted directly by common antiepileptic medications such as carbamazepine, oxcarbazepine, lamotrigine, and valproic acid, variations in the channel's primary structure could theoretically alter channel gating kinetics, drug-binding affinity, or baseline seizure thresholds. Consequently, common polymorphisms in SCN1A have long been primary candidates for pharmacogenomic research aiming to explain individual variability in seizure management.
State of Pharmacogenomic and Clinical Evidence
Decades of pharmacogenomic investigation into rs2298771 have generated conflicting results, categorizing the evidence base as limited and preliminary. Early candidate-gene studies reported that specific alleles or genotypes, particularly homozygous carriers, might exhibit altered responsiveness or resistance to sodium channel blockers like carbamazepine or valproate. Some regional cohorts also noted minor differences in general seizure susceptibility. However, multiple subsequent large-scale multi-ethnic cohorts and meta-analyses failed to replicate statistically significant associations after adjusting for multiple testing. Resources like PharmGKB catalog rs2298771 annotations at Level 4 evidence, reflecting low-level, unvalidated observational findings without clinical consensus. International pharmacogenomics consortia such as CPIC have not established dosing guidelines for this variant.
Population Frequency and Ancestral Distribution
The rs2298771 variant is a common polymorphism observed across diverse global ancestries. Genomic databases including gnomAD indicate that the minor allele frequency ranges between approximately 0.20 and 0.45 depending on the ancestral background evaluated. The variant is observed at high frequencies in South Asian, European, and East Asian populations, demonstrating that millions of healthy individuals globally carry one or two copies of the alternate allele. The widespread prevalence of this variant in asymptomatic human populations further underscores that rs2298771 is not inherently pathogenic or causative of genetic disease on its own.
Interpreting Results and Clinical Implications
Discovering an rs2298771 genotype via personal genomic testing or consumer arrays cannot diagnose epilepsy, predict future seizure disorders, or forecast how a person will respond to specific anticonvulsant therapies. Anti-seizure medication selection and dosing depend on multiple clinical factors, including seizure classification, organ function, tolerability, and other well-validated pharmacogenomic markers such as HLA alleles associated with cutaneous adverse reactions. Because current clinical guidelines do not recognize rs2298771 as an actionable biomarker, patients should never initiate, alter, or discontinue any prescribed antiepileptic therapy without direct supervision and guidance from a neurologist, physician, or clinical pharmacist.
How common is this variant?
The rs2298771 variant is common globally, with minor allele frequencies typically ranging between 0.20 and 0.45 across diverse continental groups in reference databases such as gnomAD.
Frequently asked questions
Does carrying the rs2298771 variant mean I have Dravet syndrome or severe epilepsy?
No, rs2298771 is a common, benign polymorphism present in tens of millions of healthy individuals worldwide. Severe epileptic encephalopathies like Dravet syndrome are caused by rare, highly damaging mutations in SCN1A rather than common variants like rs2298771.
Can rs2298771 testing determine which seizure medication I should take?
No, current scientific evidence for rs2298771 is considered limited and conflicting. Major clinical pharmacogenetics consortia do not recommend using this variant to guide the selection or dosage of antiepileptic drugs.
Why do some studies describe this variant as A/G and others as C/T?
This difference arises from whether a study reports the DNA sequence based on the forward plus genomic strand or the complementary minus strand where SCN1A is transcribed. In pharmacogenomics literature, the A>G coding designation (c.3184A>G) frequently corresponds to T>C in genomic strand reports.
Should I change my antiepileptic medication dose based on my genotype?
You should never adjust, start, or discontinue any medication based on genetic testing results alone. Medication dosing must always be managed in consultation with your prescribing neurologist, physician, or clinical pharmacist.
Sources & further reading
Educational information only, last refreshed 9/7/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs2298771?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in SCN1A
This variant in the SCN1A gene influences sodium channel expression and has been associated with altered dose requirements and clinical response to anti-seizure medications including phenytoin and carbamazepine.
Intronic regulatory variant in SCN1A associated via clinical PGx studies with altered therapeutic dosing requirements and pharmacoresistance to carbamazepine and phenytoin.
A variant in the SCN1A gene that may influence the effective dosage and side-effect profile of phenytoin and other anti-epileptic drugs.